Wells Mandy J, Jamieson Katharine, Markham Tamsyn C W, Green Sue M, Fader Mandy J
Mandy J. Wells, MSc, MClinRes, Honorary Consultant Nurse Researcher, Plymouth Hospitals NHS Trust, Plymouth, Devon, England. Katharine Jamieson, Diploma, formerly Research Nurse, Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom. Tamsyn C. W. Markham, PhD, formerly Research Assistant, Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom. Sue M. Green, PhD, Senior Lecturer, Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom. Mandy J. Fader, PhD, Professor, Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom.
J Wound Ostomy Continence Nurs. 2014 Jul-Aug;41(4):371-8. doi: 10.1097/WON.0000000000000040.
The primary aims of this study were to test the methodology for use in a future randomized control trial and to investigate the effect of drinking caffeinated versus decaffeinated fluids on symptoms of overactive bladder (OAB) in women.
A double-blind, randomized, crossover study was conducted.
Fourteen community-dwelling women newly diagnosed with OAB and a history of caffeine consumption were randomly allocated to group A (14-day caffeinated drink period followed by 14-day decaffeinated drink period) or group B (14-day decaffeinated drink period followed by 14-day caffeinated drink period). The periods were preceded by a 14-day run-in period and interspersed with a 14-day washout period. Primary outcomes were episodes of urgency, frequency, volume per void, and incontinence obtained each period on 3-day bladder diaries. Secondary outcome measures were OAB symptom severity and health-related quality of life (QOL) recorded each period using International Consultation on Incontinence-Overactive Bladder Module (ICIQ-OAB) and ICIQ-OAB-Quality of Life (ICIQ-OABqol) tools. Effects of caffeine reduction were measured each day using visual analogue scales.
Eleven participants completed the study. A significant reduction in urgency (P < .01) and frequency (P < .05) of urinary voids on day 3 of the diary, total ICIQ-OAB score (P < .01), and a non-significant directional change for the total ICIQ-OABqol score (P = .065) was found using sign tests for the period of decaffeinated compared to caffeinated drink intake. No significant differences were found for any caffeine withdrawal measures.
Despite the small sample size, this pilot study demonstrated that reducing caffeine intake may alleviate the severity of some symptoms and health-related QOL factors associated with OAB. Furthermore, caffeine substitutes were well tolerated.
本研究的主要目的是测试用于未来随机对照试验的方法，并调查饮用含咖啡因饮料与无咖啡因饮料对女性膀胱过度活动症（OAB）症状的影响。
进行了一项双盲、随机、交叉研究。
14名新诊断为OAB且有咖啡因摄入史的社区女性被随机分配到A组（14天饮用含咖啡因饮料期，随后是14天饮用无咖啡因饮料期）或B组（14天饮用无咖啡因饮料期，随后是14天饮用含咖啡因饮料期）。在各阶段之前有一个14天的导入期，并穿插一个14天的洗脱期。主要结局是在3天膀胱日记中每个阶段记录的尿急发作次数、排尿频率、每次尿量和尿失禁情况。次要结局指标是使用国际尿失禁咨询委员会膀胱过度活动症模块（ICIQ - OAB）和ICIQ - OAB生活质量（ICIQ - OABqol）工具在每个阶段记录的OAB症状严重程度和健康相关生活质量（QOL）。每天使用视觉模拟量表测量减少咖啡因摄入的效果。
11名参与者完成了研究。与饮用含咖啡因饮料期相比，在饮用无咖啡因饮料期使用符号检验发现，日记第3天排尿的尿急（P < 0.01）和频率（P < 0.05）显著降低，ICIQ - OAB总分（P < 0.01），ICIQ - OABqol总分有非显著的方向性变化（P = 0.065）。在任何咖啡因戒断措施方面均未发现显著差异。
尽管样本量较小，但这项初步研究表明，减少咖啡因摄入可能会减轻与OAB相关的一些症状的严重程度以及健康相关的生活质量因素。此外，咖啡因替代品耐受性良好。
